BCEIE › News › PANACEABIO

Regulatory

Panacea Biotec has received four Demand Orders from the Office of the Assistant Commissioner of Income Tax, Delhi under Section…

Panacea Biotec (BSE: PANACEABIO) said it has received four Demand Orders from the Office of the Assistant Commissioner of Income Tax, Delhi under Section 156 of the Income Tax Act, 1961 ("Act") imposing penalty on. The company is valued at about ₹2,257 crore.

BCEIE News Desk · Published 28 Sept 2026, 07:31 pm IST · Filing received 26 Sept 2026, 05:28 pm IST

What happened

Panacea Biotec (BSE: PANACEABIO) informed the stock exchanges on 26 September 2026 at 05:28 PM that it has received four Demand Orders from the Office of the Assistant Commissioner of Income Tax, Delhi under Section 156 of the Income Tax Act, 1961 ("Act") imposing penalty on.

Company snapshot

Panacea Biotec is a small-cap company, with a market value of about ₹2,257 crore.

The stock last traded at ₹368.5, against a 52-week range of ₹292.4–₹647 (43.0% below the high).

Before this filing the shares had moved −5.3% over the month and −34.1% over three months. Average daily turnover over the last 20 sessions was about ₹4.03 crore.

Promoters held 72.48% at the end of Q1 FY27. Foreign institutions owned 2.31% and domestic institutions 2.25%.

What history shows

BCEIE's records show 1 previous regulatory filing from the company since May 2026.

Market-wide, 5,432 regulatory filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.

Past reactions describe what happened before; they are not a forecast.

Market reaction so far

Since the filing, the stock has fallen 1.1%, from ₹372.6 before the disclosure to ₹368.5 (last close).

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.